Company / Accounts Receivable
Xeris Biopharma Holdings, Inc. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$51.0M
FY2025
5-year range
$17.5M / $51.0M
FY2021-FY2025
Trend
+26.3%
vs FY2024
Sector context
#70 of 113
Health Care
What the data says
At $51M, Xeris Biopharma Holdings, Inc.'s accounts receivable ranks #70 of 113 in the Health Care sector. Accounts Receivable has increased for 5 consecutive years, from $7M in FY2020 to $51M in FY2025.
Based on SEC 10-K filings.
$51M in FY2025 with a 5-year CAGR of +49.3%.
Improved from $39M to $51M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +18.3%
- 5-Year CAGR
- +49.3%
- 10-Year CAGR
- -
Sector benchmark
#70 of 113 in Health CareTop 62% of 113This company $51.0M Sector average $1.1B
▼
-95.5% below sector average
Key checks
Key Insights
- Xeris Biopharma Holdings, Inc.'s accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +49.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 26.3% year-over-year.
- Ranks #70 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $51.0M | +26.3% |
| FY2024 | $40.4M | +3.1% |
| FY2023 | $39.2M | +27.1% |
| FY2022 | $30.8M | +76.6% |
| FY2021 | $17.5M | +153.9% |
| FY2020 | $6.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026